Cybersonics Purchases the Assets of Omnisonics Medical Technologies

ERIE, PENNSYLVANIA – February 7, 2011 - Cybersonics Inc, has acquired substantially all assets of former Wilmington, MA based Omnisonics Medical Technology, Inc.

The purchased assets, which were sold pursuant to Omnisonics' March 2009 Bankruptcy filing, consist of the intellectual property of OmniSonics including issued patents and trademarks, related records, patent applications, FDA regulatory clearances and certain equipment and devices.

Omnisonics developed, patented and received U.S. FDA 510-K marketing clearance for the OmniWave® technology to remove thrombus in the peripheral vasculature, including its use with the infusion of physician-specified fluids. This catheter based technology delivers transverse ultrasonic energy to targeted thrombus in a diseased blood vessel, without damaging the surrounding vessel
walls.

Since the acquisition, Cybersonics has advanced the OmniWave® technology to further improve clinical efficacy and ease of use in the clearing of thrombus. The Company plans to commercialize this catheter based ultrasonic technology through sales and marketing alliance(s) that address the wide range of clinical applications for improved thrombus clearing in vessels, shunts and blood access catheters.

Cybersonics will present an overview of this acquisition and highlight their recent advances in the OmniWave® ultrasound technology at the medtech IN3 West Conference, Las Vegas, February 22 – 24, 2011.

Cybersonics, Inc. is an established leader in the application of ultrasonics for the medical and other specialty markets. Currently marketed medical products that the company has developed and manufacture include the Gyrus ACMI (Olympus) CyberWand® Dual Ultrasonic Lithotriptor and the Flowcardia (C.R. Bard) CROSSER® CTO Recanalization Catheter.

# # # #

Contact:
Rick Davies
801-352-8500
info@cybersonics-inc.com
www.cybersonics-inc.com